4.6 Article

Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension

期刊

EUROPEAN RESPIRATORY JOURNAL
卷 55, 期 6, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.00041-2020

关键词

-

资金

  1. British Heart Foundation Intermediate Clinical Fellowship [FS/18/13/3328]
  2. Wellcome Trust Clinical Research Career Development Fellowship [205188/Z/16/Z]

向作者/读者索取更多资源

There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAH(no-LD) (n=303), and those with minor/mild emphysema or fibrosis were described as IPAH(mild-LD) (n=190). Survival was significantly better in IPAHno-LD than in IPAH(mild-LD) (1-and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAH(no-LD) and IPAH(mild-LD), independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D-LCO), lower exercise capacity and a diagnosis of IPAH(mild-LD) (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAH(no-LD), but not IPAH(mild-LD). A proportion of patients with IPAH(no-LD) had a DLCO <45%; these patients had poorer survival than patients with D-LCO < 45%, although they demonstrated improved exercise capacity following treatment. The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D-LCO may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据